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104 M.-H. Yang et al.Introduction
Alzheimer’s disease (AD) is the most common cause of de-
mentia in late life and is a devastating neurological disorder
accounting for about 50% of all dementias, which involve
multiple pathologies in the complex biological system of the
brain.1 It is a progressive disease, which means that grad-
ually more areas of the brain are damaged. As this happens,
the symptoms become more severe. Scientists do not yet
fully understand the processes that result in the cata-
strophic brain damages associated with AD, and it is difficult
and time consuming to diagnose AD at its very early stage.2,3
In our previous study, downregulation of activity-
dependent neuroprotector homeobox protein (ADNP,
124 kDa) was evidenced in AD patients. ADNP is a glial cell
mediator of a vasoactive intestinal peptide associated with
neuroprotection and is essential for brain development. In
the hippocampus, cerebral cortex, and cerebellum, the
highly conserved ADNP gene is expressed abundantly.4,5
ADNP is implicated in the maintenance of cell survival
through modulation of p53 expression.6 It also protects
cerebral cortical neurons against b-amyloid 1-42, the major
AD toxic peptide, and inhibits b-amyloid 1-40 aggregation in
brain.7
To enhance our understanding of the mechanism of neu-
roprotection, NAP (NAPVSIPQ, amino acid sequence from354
to 361), an eight-amino-acid femtomolar-acting peptide
fragment of ADNP, was added into the SH-SY5Y cell culture
medium. After incubationwithNAP, SH-SY5Y cellswere lysed
by cell lysis buffer, and cell lysate proteinswere identified by
reverse phase nano-high performance liquid chromatog-
raphy electrospray ionization tandem mass spectrometry
(RPenano-HPLCeESIeMS/MS). These results will allow us to
understand the mechanism of the NAP-induced neuro-
protective activity in neuroblastoma cells.s,
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.Materials and methods
Cell culture
SH-SY5Y cells (neuroblastoma cells) were maintained at
37 C and 5% CO2 in a 1:1 mixture of Eagle’s Minimum
Essential Medium and Ham’s F12 Medium supplemented with
10% fetal bovine serum (HyClone Laboratories, Logan, UT,
USA), 1% penicillin/streptomycin (Gibco, Grand Island, NY,
USA), and 44mM NaHCO3. After 3 days, NAP (100mM) was
added to the mixture and incubated for 12 hours.T
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After incubation with NAP, SH-SY5Y cells were washed using
phosphate-buffered saline and lysed using cell lysis buffer
(3500-1, Epitomics, Inc., Burlingame, CA, USA). Cell lysates
were centrifuged at 1500 g for 10 minutes at 4 C and
filtered through a 0.8 mm filter.
Cell lysate samples (100 mL) were reduced, alkylated,
and then digested with trypsin using standard protocols.
Formic acid (2 mL) was added to each sample prior to mass
spectrometric analysis for protein identification.
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Complex peptide mixtures were separated using RPenano-
HPLCeESIeMS/MS. Protein tryptic digests were fractionated
at a flow rate of 400 nL/min, using a nano-HPLC system
(nanoACQUITY UPLC,Waters, Milford, MA, USA) coupled to an
ion trap mass spectrometer (LTQ Orbitrap Discovery Hybrid
FTMS, Thermo, San Jose, CA, USA) equipped with
an electrospray ionization source. For RPenano-
HPLCeESIeMS/MS, a sample (2 mL) of the desired peptide
digest was loaded into the reverse-phase column (Symmetry
C18, 5 mm, 180 mm  20 mm) by an autosampler. RP separa-
tion was performed using a linear acetonitrile gradient from
99% buffer A (100% DI water/0.1% formic acid) to 85% buffer B
(100% acetonitrile/0.1% formic acid) in 100 minutes using the
micropump. The separation was performed on a C18 micro-
capillary column (BEH C18, 1.7 mm, 75 mm  100 mm) using
the nano-separation system. As peptides eluted from the
microcapillary column, they were electrosprayed into the
ESIeMS/MS with the application of a distal 2.1 kV spraying
voltage, while maintaining the heated capillary at a tem-
perature 200 C. Each cycle of one full scan mass spectrum
(m/z 400e2000) was followed by four data-dependent tan-
dem mass spectra, with collision energy set at 35%.Figure 1 Proteineprotein interaction pathways.Database search
For protein identification, Mascot software (version 2.2.1,
Matrix Science, London, UK)was used to search the Swiss-Prot
human protein sequence database. Protein identifications
wereconsidered tobepositivewhenMowse scores> 100were
considered significant (p < 0.05). Proteins were initially an-
notated by similar searches using UniProtKB/Swiss-Prot da-
tabases. The proteineprotein interaction pathways were
analyzed using String 9.0 Web software, Copyright ª
2000e2011 CPR, EMBL, SIB, KU, TUD and UZH.
Results
In this study, a proteomic analysis was conducted to
identify protein changes associated with NAP-induced
neuroprotective activity in neuroblastoma cells. Experi-
mental results reported identification of a total of six pro-
teins with higher confidence levels (at least 3 unique
peptide sequences matched). Stathmin is a highly
conserved 17 kDa protein. It functions as an important
regulatory protein during neuronal differentiation, in
microtubule dynamics, and in modulating membrane
interaction with the cytoskeleton during neurite outgrowth.Proteins identified in this study were marked.
106 M.-H. Yang et al.It was observed to be involved in neurogenesis, cell dif-
ferentiation, and signal transducer activity, and was found
in the cell lysate samples from SH-SY5Y cells with NAP.
Stathmin may act as a signaling relay phosphoprotein for
second messenger signaling pathways involved in cell pro-
liferation and differentiation. Biological processes, molec-
ular functions, and subcellular locations of stathmin are
listed in Table 1. The proteineprotein interaction pathways
were analyzed by String 9.0 Web software and two proteins
identified in this study were marked (Fig. 1).
Discussion
NAP is a neuroprotective peptide with functional similar-
ity to activity-dependent neurotropic factor-9. Previous
studies indicated that NAP could prevent ethanol-induced
developmental toxicity and embryo toxicity, and has po-
tential importance of ethanol effects on neuroprotective
drug in the pathophysiology of fetal alcohol syndrome.8,9
In AD research, apolipoprotein E (Apo E) has been impli-
cated as a risk factor. NAP also provides neuroprotection
in Apo E deficiency, and is able to break amyloid plaques
or degrade b-amyloid toxicity.9,10 Neurofibrillary tangles
composed of aggregation, which are formed by hyper-
phosphorylated tau protein, are one of the major patho-
logical hallmarks of AD. NAP treatment can reduce the tau
pathology and the extent of phosphorylation at the early
stages of AD.11
Stathmin expression is strongest in the placenta and
embryonic brain, spinal cord, and cerebellum, followed by
in the thymus, bone marrow, testis, and fetal liver. It is
involved in the neuroprotective effect of pituitary adeny-
late cyclase-activating polypeptide in PC12 cells subjected
to serum starvation.12 In this study, NAP was added to the
SH-SY5Y cell culture medium and stathmin was upregulated
in the NAP group.
Our present study further demonstrated a relationship
between NAP and neuroblastoma cells. Furthermore, we
have identified successfully at least one protein associated
with NAP: stathmin. Of the candidates identified, our re-
sults showed that NAP may provide additional neuro-
protection in AD. According to our preliminary proteomic
data, stathmin level may serve as a new and direct thera-
peutic indicator for NAP treatment. However, results of
these studies still need to be verified by larger clinical
studies. In conclusion, these proteins are valuable for the
identification of differentially expressed proteins involved
in the proteomics database and for screening biomarkers
for further study of AD.Acknowledgments
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